“Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies”, J of Skin, vol. 6, no. 2, p. s11, Mar. 2022, doi: 10.25251/skin.6.supp.11.